Dementia in Parkinson's disease

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Current Opinion in Neurology

• Publication date

  2008-12-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1097/WCO.0b013e3283168df0PMID 18989112
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Disturbance of automatic auditory change detection in dementia associated with Parkinson's disease: A mismatch negativity study.

  2010cited by this paper
• A controlled trial of antidepressants in patients with Parkinson disease and depression

  2009cited by this paper
• Montreal Cognitive Assessment Performance in Patients with Parkinson's Disease with “Normal” Global Cognition According to Mini‐Mental State Examination Score

  2009cited by this paper
• Depression associated with dementia with Lewy bodies (DLB) and the effect of somatotherapy

  2009cited by this paper
• Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy.

  2009cited by this paper
• Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.

  2009cited by this paper
• Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.

  2008cited by this paper
• Cortical α-synuclein load is associated with amyloid-β plaque burden in a subset of Parkinson’s disease patients

  2008cited by this paper
• [11C]PIB binding in Parkinson's disease dementia

  2008cited by this paper
• Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study

  2008cited by this paper
• EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up.

  2008cited by this paper
• A systematic review of prevalence studies of depression in Parkinson's disease

  2008cited by this paper
• α-Synuclein gene duplication is present in sporadic Parkinson disease

  2008cited by this paper
• Determinants of disability and quality of life in mild to moderate Parkinson disease

  2008cited by this paper
• Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease

  2008cited by this paper
• Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study.

  2008cited by this paper
• Age and dementia-associated atrophy predominates in the hippocampal head and amygdala in Parkinson's disease.

  2008cited by this paper
• Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study.

  2008cited by this paper
• The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years

  2008cited by this paper
• Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia

  2008cited by this paper
• In vitro high affinity α-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain

  2008cited by this paper
• Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease

  2008cited by this paper
• Cognitive screening for dementia and mild cognitive impairment in assisted living: comparison of 3 tests.

  2008cited by this paper
• Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson diseaseSYMBOL

  2008cited by this paper
• Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration.

  2008cited by this paper
• Dementia and survival in Parkinson disease

  2008cited by this paper
• α-Synuclein gene duplication is present in sporadic Parkinson disease

  2008cited by this paper
• Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems

  2008cited by this paper
• Brain N-acetylaspartate is Reduced in Parkinson Disease With Dementia

  2008cited by this paper
• The progression of pathology in longitudinally followed patients with Parkinson’s disease

  2008cited by this paper
• Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease

  2007cited by this paper
• Changes in network activity with the progression of Parkinson's disease.

  2007cited by this paper
• Brain mapping as a tool to study neurodegeneration

  2007cited by this paper
• Apolipoprotein E gene polymorphism, total plasma cholesterol level, and Parkinson disease dementia.

  2007cited by this paper
• [Akatinol memantine in the therapy of cognitive disorders in Parkinson's disease].

  2007cited by this paper
• DLB and PDD boundary issues

  2007cited by this paper
• Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies.

  2007cited by this paper
• Evolution of cognitive dysfunction in an incident Parkinson's disease cohort.

  2007cited by this paper
• Antipsychotic Drug Use and Mortality in Older Adults with Dementia

  2007cited by this paper
• Clinical diagnostic criteria for dementia associated with Parkinson's disease

  2007cited by this paper
• Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force

  2007cited by this paper
• The effect of age of onset of PD on risk of dementia

  2007cited by this paper
• Parkinson disease, 10 years after its genetic revolution: Multiple clues to a complex disorder

  2007cited by this paper
• Course of cognitive decline in Parkinson's disease: A meta-analysis

  2007cited by this paper
• Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease.

  2007cited by this paper
• Proteomic Identification of Novel Proteins in Cortical Lewy Bodies

  2007cited by this paper
• Effect of quetiapine in psychotic Parkinson's disease patients: A double‐blind labeled study of 3 months' duration

  2007cited by this paper
• Profile of cognitive impairment in dementia associated with Parkinson’s disease compared with Alzheimer’s disease

  2007cited by this paper
• Efficacy and Safety of Galantamine in Patients with Dementia with Lewy Bodies: A 24-Week Open-Label Study

  2007cited by this paper
• MRI confirms mild cognitive impairments prodromal for Alzheimer's, vascular and Parkinson-Lewy body dementias.

  2007cited by this paper
• Dementia in Parkinson’s disease: diffusion tensor imaging

  2007cited by this paper
• Metabolic brain networks associated with cognitive function in Parkinson's disease

  2007cited by this paper
• Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies

  2007cited by this paper
• Tau and α‐synuclein in susceptibility to, and dementia in, Parkinson's disease

  2007cited by this paper
• Presynaptic α-Synuclein Aggregates, Not Lewy Bodies, Cause Neurodegeneration in Dementia with Lewy Bodies

  2007cited by this paper
• Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease.

  2006cited by this paper
• Open‐label flexible‐dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease

  2006cited by this paper
• Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease.

  2006cited by this paper
• Changes in motor subtype and risk for incident dementia in Parkinson's disease

  2006cited by this paper
• Apolipoprotein E and dementia in Parkinson disease: a meta-analysis.

  2006cited by this paper
• Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease

  2006cited by this paper
• Subtypes of mild cognitive impairment in parkinson's disease: Progression to dementia

  2006cited by this paper
• Pyridostigmine treatment trial in neurogenic orthostatic hypotension.

  2006cited by this paper
• Clinical phenotype of Parkinson disease dementia

  2006cited by this paper
• A magnetic resonance imaging study of patients with Parkinson’s disease with mild cognitive impairment and dementia using voxel-based morphometry

  2006cited by this paper
• Relationship of apolipoprotein E and age at onset to Parkinson disease neuropathology.

  2006cited by this paper
• Bladder dysfunction in Parkinsonism: Mechanisms, prevalence, symptoms, and management

  2006cited by this paper
• Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated care giver stress

  2006cited by this paper
• Cognitive decline correlates with neuropathological stage in Parkinson's disease.

  2006cited by this paper
• Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease

  2006cited by this paper
• Beta-Amlyoid 1–42 and Tau-Protein in Cerebrospinal Fluid of Patients with Parkinson’s Disease Dementia

  2006cited by this paper
• Statistical Power of Studies Examining the Cognitive Effects of Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease

  2006cited by this paper
• Relationship of apolipoprotein E and age at onset to Parkinson disease neuropathology.

  2006cited by this paper
• Cognitive profiles of individual patients with Parkinson's disease and dementia: Comparison with dementia with lewy bodies and Alzheimer's disease

  2006cited by this paper
• REM sleep behavior disorder

  2006cited by this paper
• Attentional deficits affect activities of daily living in dementia-associated with Parkinson’s disease

  2006cited by this paper
• Differences in neuropathologic characteristics across the Lewy body dementia spectrum

  2006cited by this paper
• Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis.

  2006cited by this paper
• Associations between family history of Parkinson's disease and dementia and risk of dementia in Parkinson's disease: A community‐based, longitudinal study

  2006cited by this paper
• Association between amantadine and the onset of dementia in Parkinson's disease

  2006cited by this paper
• Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop

  2006cited by this paper
• 0781 Delusions and hallucinations in dementia with Lewy bodies: Worsening with memantine

  2005cited by this paper
• The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment

  2005cited by this paper
• Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study

  2005cited by this paper
• Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial

  2005cited by this paper
• Double‐blind, placebo‐controlled, unforced titration parallel trial of quetiapine for dopaminergic‐induced hallucinations in Parkinson's disease

  2005cited by this paper
• Cognitive profile of patients with newly diagnosed Parkinson disease

  2005cited by this paper
• Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers

  2005cited by this paper
• Genetic association between the APOE*4 allele and Lewy bodies in Alzheimer disease

  2005cited by this paper
• Symptoms of sleep disturbance in persons with Alzheimer's disease and normal elderly

  2005cited by this paper
• Delusions and hallucinations in dementia with Lewy bodies: Worsening with memantine

  2005cited by this paper
• Amygdalar and hippocampal MRI volumetric reductions in Parkinson's disease with dementia

  2005cited by this paper
• Diagnosis and management of dementia with Lewy bodies

  2005cited by this paper
• Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging

  2005cited by this paper
• Rivastigmine for dementia associated with Parkinson's disease.

  2004cited by this paper
• Randomized placebo‐controlled trial of donepezil in cognitive impairment in Parkinson's disease

  2004cited by this paper
• Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications.

  2004cited by this paper
• The rate of cognitive decline in Parkinson disease.

  2004cited by this paper
• Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms.

  2004cited by this paper
• Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls.

  2004cited by this paper

• The association between probable sarcopenia, non-motor symptoms, and fall-related outcomes in parkinson’s disease

  2026cites this paper
• Comparative diagnostic efficacy of neuromelanin MRI vs. dopamine transporter (DAT) imaging in Parkinson's disease: A systematic review.

  2025cites this paper
• Memory from nonsense syllables to novels: A survey of retention

  2024cites this paper
• Cognitive disorders in advanced Parkinson’s disease: challenges in the diagnosis of delirium

  2024cites this paper
• Network nature of ligand-receptor interactions underlies disease comorbidity in the brain

  2024cites this paper
• Neuropsychological Assessment for Early Detection and Diagnosis of Dementia: Current Knowledge and New Insights

  2024cites this paper
• Radiographic abnormalities and their clinical significance in patients with Parkinson disease who receive deep brain stimulation implants.

  2024cites this paper
• Influence of care partner presence on outcomes of people with Parkinson’s disease: a systematic review

  2024cites this paper
• NEUROPSYCHIATRIC ISSUES IN PARKINSON DISEASE (PD) PATIENTS: CLINICAL FEATURES AND GENETICS PREDISPOSITION

  2023cites this paper
• The Impact of Sex‐Specific Survival on the Incidence of Dementia in Parkinson's Disease

  2023cites this paper
• Correlation of metal ions with specific brain region volumes in neurodegenerative diseases

  2023cites this paper
• Effects of proprioceptive neuromuscular facilitation on components of functional physical activity in patients with Parkinson’s disease

  2023cites this paper
• Levodopa, homocysteine and Parkinson's disease: What's the problem?

  2023cites this paper
• A new look at memory retention and forgetting.

  2022cites this paper
• Sleep disturbance in caregivers of individuals with Parkinsonism: a systematic review and meta-analysis

  2022cites this paper
• Predictors of two-year mortality in patients with dementia with Lewy bodies

  2022cites this paper
• Prediction and early biomarkers of cognitive decline in Parkinson disease and atypical parkinsonism: a population-based study

  2022cites this paper
• A novel approach to understanding Parkinsonian cognitive decline using minimum spanning trees, edge cutting, and magnetoencephalography

  2021cites this paper
• Atypical parkinsonism, parkinsonism-plus syndromes and secondary parkinsonian disorders

  2021cites this paper
• Differentiating dementia with Lewy bodies from Alzheimer's disease and Parkinson's disease dementia: an update on imaging modalities

  2021cites this paper
• The Role of Salivary Biomarkers in the Early Diagnosis of Alzheimer’s Disease and Parkinson’s Disease

  2021cites this paper
• Outcomes of Patients With Parkinson Disease Undergoing Cervical Spine Surgery for Radiculopathy and Myelopathy With Minimum 2-Year Follow-up

  2021cites this paper
• Effect of Deep Brain Stimulation on Parkinson Disease Dementia: A Systematic Review and Meta-analysis

  2021cites this paper
• Fluid Biomarkers for Synaptic Dysfunction and Loss

  2020cites this paper
• α-Synuclein heteromers with ß-amyloid and tau decreased in red blood cells of Alzheimer’s disease and Lewy Body dementia patients.

  2020cites this paper
• Combined subthalamic and nucleus basalis of Meynert deep brain stimulation for Parkinson’s disease with dementia (DEMPARK-DBS): protocol of a randomized, sham-controlled trial

  2020cites this paper
• Parkinson’s disease and the non-motor symptoms: hyposmia, weight loss, osteosarcopenia

  2020cites this paper
• APOE4 exacerbates α-synuclein pathology and related toxicity independent of amyloid

  2020cites this paper
• Stem Cell-Based Therapies for Parkinson Disease

  2020cites this paper
• Neuroinflammation and Alpha-Synuclein Oligomer Toxicity in the Pathogenesis of Lewy Body Dementia and Parkinson's Disease

  2020influential citation
• Microglial activation contributes to cognitive impairments in rotenone-induced mouse Parkinson’s disease model

  2020cites this paper
• Neurocognitive mechanisms of theory of mind impairment in neurodegeneration: a transdiagnostic approach

  2019cites this paper
• The Potential Drug-Drug Interactions in Alzheimer Patients’ Treatment Alzheimer Hastalarının Tedavisinde Potansiyel İlaç-İlaç Etkileşimleri

  2019cites this paper
• Levodopa-Induced Dyskinesias and Dyskinesias-Reduced-Self-Awareness in Parkinson’s Disease: A Neurocognitive Approach

  2019cites this paper
• Dementia spectrum disorders: lessons learnt from decades with PET research

  2019cites this paper
• Inhibition of NADPH oxidase by apocynin prevents learning and memory deficits in a mouse Parkinson's disease model

  2019cites this paper
• Neural correlates of distinct cognitive phenotypes in early Parkinson's disease.

  2019cites this paper
• Risk of dementia after Parkinson’s disease in Taiwan: a population-based retrospective cohort study using National Health Insurance claims

  2019cites this paper
• Tau is required for progressive synaptic and memory deficits in a transgenic mouse model of α-synucleinopathy

  2019cites this paper
• Altered exocytosis in chromaffin cells from mouse models of neurodegenerative diseases

  2018cites this paper
• Parkinson's disease: A review

  2018cites this paper
• Quantitative susceptibility mapping as an indicator of subcortical and limbic iron abnormality in Parkinson's disease with dementia

  2018cites this paper
• Catechol-O-methyltransferase (COMT) genetic variants are associated with cognitive decline in patients with Parkinson's disease.

  2018cites this paper
• A comparison of the treatment recommendations for neurogenic lower urinary tract dysfunction in the national institute for health and care excellence, European Association of Urology and international consultations on incontinence guidelines

  2018cites this paper
• Lewy Body Disease: Clinical and Pathological “Overlap Syndrome” Between Synucleinopathies (Parkinson Disease) and Tauopathies (Alzheimer Disease)

  2018cites this paper
• Theory of mind, empathy and emotion perception in cortical and subcortical neurodegenerative diseases.

  2018cites this paper
• Alpha-synuclein oligomers impair memory through glial cell activation and via Toll-like receptor 2.

  2018cites this paper
• Weight Loss and Malnutrition in Patients with Parkinson's Disease: Current Knowledge and Future Prospects

  2018cites this paper
• Cognitive Impairment in Parkinson s Disease

  2018cites this paper
• Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson’s disease

  2018cites this paper
• Dementia in Parkinson’s Disease Revisited: In the Light of Fischer’s Disease

  2017cites this paper
• Effects of regiolects on the perception of developmental foreign accent syndrome

  2017cites this paper
• Seeding and transgenic overexpression of alpha‐synuclein triggers dendritic spine pathology in the neocortex

  2017cites this paper
• Changes of brain structure in Parkinson's disease patients with mild cognitive impairment analyzed via VBM technology.

  2017cites this paper
• Cognitive and Neuropsychiatric Features of Early Parkinson's Disease

  2017cites this paper
• Serotonergic Approaches in Parkinson's Disease: Translational Perspectives, an Update.

  2017cites this paper
• Neonatal AAV delivery of alpha-synuclein induces pathology in the adult mouse brain

  2017cites this paper
• Depression in Parkinson's Disease: The Contribution from Animal Studies

  2017cites this paper
• Dementia with Lewy Bodies

  2017cites this paper
• Nonmotor Symptoms and Natural History of Parkinson's Disease: Evidence From Cognitive Dysfunction and Role of Noninvasive Interventions.

  2017cites this paper
• Association of plasma homocysteine, vitamin B12 and folate levels with cognitive function in Parkinson's disease: A meta-analysis.

  2017cites this paper
• Apolipoprotein E and Alzheimer’s disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins

  2017cites this paper
• Biological and Behavioural Markers of Parkinson’s Disease

  2017cites this paper
• La cognition sociale dans le vieillissement normal et pathologique Social cognition in normal and pathological aging

  2016cites this paper
• Understanding the temporal dynamics of visual hallucinations in Parkinson's Disease with dementia

  2016cites this paper
• Chapter 14 Deep Brain Stimulation for Memory Dysfunction

  2016cites this paper
• Social cognition in normal and pathological aging.

  2016cites this paper
• Diagnostic Accuracy and Confidence in the Clinical Detection of Cognitive Impairment in Early-Stage Parkinson Disease

  2016cites this paper
• MMSE and MoCA in Parkinson’s disease and dementia with Lewy bodies: a multicenter 1-year follow-up study

  2016cites this paper
• Neuroprotective Effects of Simvastatin and Cilostazol in l-Methionine-Induced Vascular Dementia in Rats

  2016cites this paper
• Val66Met BDNF polymorphism is associated with Parkinson's disease cognitive impairment.

  2016cites this paper
• Aldehyde dehydrogenase 2 is associated with cognitive functions in patients with Parkinson’s disease

  2016cites this paper
• Voxel-based morphometry to detect effect of APOE on brain gray matter changes in Parkinson's Disease.

  2016cites this paper
• Serum Autoantibodies as Biomarkers for Parkinsons Disease: Background and Utility

  2015cites this paper
• Non-motor signs in Parkinson's disease: a review.

  2015cites this paper
• Non-motor signs in Parkinson ’ s disease : a review

  2015cites this paper
• Antioxidant and anticholinesterase investigations of Rumex hastatus D. Don: potential effectiveness in oxidative stress and neurological disorders

  2015cites this paper
• Comparison of frequencies of non motor symptoms in Indian Parkinson’s disease patients on medical management versus deep brain stimulation: A case-control study

  2015cites this paper
• Clinically meaningful parameters of progression and long-term outcome of Parkinson disease: An international consensus statement.

  2015cites this paper
• STEP61 is a substrate of the E3 ligase parkin and is upregulated in Parkinson’s disease

  2015cites this paper
• Role of G-protein coupled receptor kinase 5 gene in cognitive impairment in Parkinson's disease.

  2015cites this paper
• Biomarkers of cognitive decline in Parkinson's disease.

  2015cites this paper
• MASTERARBEIT / MASTER’S THESIS

  2015cites this paper
• Non-motor signs in Parkinson's disease: a review.

  2015cites this paper
• CARACTERÍSTICAS DEMOGRÁFICAS E MOTORAS ASSOCIADAS COM A OCORRÊNCIA DE COMPLICAÇÕES NEUROPSIQUIÁTRICAS E DO SONO EM PACIENTES COM

  2014cites this paper
• The impact of dementia development concurrent with Parkinson's disease: a new perspective.

  2014cites this paper
• Characterizing Spoken Discourse in Individuals with Parkinson Disease Without Dementia

  2014cites this paper
• Validation and attempts of revision of the MDS-recommended tests for the screening of Parkinson's disease dementia.

  2014cites this paper
• Tau acts as a mediator for Alzheimer's disease‐related synaptic deficits

  2014cites this paper
• Dementia – The real problem for patients with Parkinson's disease

  2014cites this paper
• Functional brain imaging of cognitive status in Parkinson's disease

  2014cites this paper
• Depression increases in patients with Parkinson?s disease according to the increasing severity of the cognitive impairment.

  2014cites this paper
• Prevalence of nocturia in Parkinson’s disease patients from various ethnicities

  2014cites this paper
• Subjective memory complaints, depressive symptoms and cognition in Parkinson's disease patients

  2014cites this paper
• ASMT gene expression correlates with cognitive impairment in patients with recurrent depressive disorder

  2014cites this paper
• The Neuropsychological Assessment Battery Categories Test as a Measure of Executive Dysfunction in Patients With Parkinson’s Disease and Essential Tremor: An Exploratory Study

  2014cites this paper
• Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing

  2014cites this paper
• Behavioral disorders in Parkinson's disease: the role of dopamine.

  2014cites this paper
• Amyloid Proteins : A Large Family of Unrelated Proteins with Some Shared Features

  2014cites this paper
• Laser Acupuncture at HT7 Acupoint Improves Cognitive Deficit, Neuronal Loss, Oxidative Stress, and Functions of Cholinergic and Dopaminergic Systems in Animal Model of Parkinson's Disease

  2014cites this paper